Speaker 1:
0:00
Welcome to the MedEvidence Monday Minute Radio Show hosted by Kevin Gettings of WSOS St Augustine Radio and powered by Encore Research Group. Each Monday morning, dr Michael Coran calls in to bring you the latest medical updates with insightful discussions. Medevidence is where we help you navigate the real truth behind medical research, with both a clinical and research perspective. So sit back, relax and get ready to learn about the truth behind the data in medicine and health care. This is MedEvidence.
Speaker 2:
0:32
Dr Michael Coran joins us live here on the studio line, as he does every Monday morning, and this morning we're going to talk about fact versus opinion as it relates to clinical research Right, dr.
Speaker 3:
0:43
Yes, yes, kevin, good morning, how are you?
Speaker 2:
0:45
Well, doing well, doing well. There have been a lot of talk and of course, there was a study out last week that got a lot of people's attention about, I guess, ozempic and will-go-vee those drugs that a lot of Hollywood stars are using to shed pounds but they have real benefit too for people that may be dealing with stroke and heart disease too, and obesity.
Speaker 3:
1:02
Yeah, it's funny. We've been working with the chemical that is will-go-vee or ozempic. It's called semaglutide or semaglutide, and it's a drug that enhances the signaling between your liver and your brain and makes you feel full. It's a satiety hormone and because of this, people eat less and they lose weight, so it's a very, very interesting chemical. We started working with it as a diabetes drug, but in fact it works for lots of people people who have metabolic syndrome, meaning that they're overweight and out of shape. It works for people who have heart disease and no diabetes, and the most recent clinical research shows that actually prevents heart attacks and strokes.
Speaker 2:
1:49
Yeah, it could be a real game changer. Obviously A little expensive at the moment in terms of people being able to pay for it, but there was a study that came out that was all over the national media in the last week or so that indicated that both stroke and heart attack risk were diminished by people who took this drug.
Speaker 3:
2:07
Yeah, and, in fairness, there are other drugs in this class, so Lingero, for example, is a competitor, trilicity is some similar properties, so it's not just ozempic, but it's a class of drugs called GLP1 agonist. So we're not here hawking any particular product. Just to be clear, it's a group of products.
Speaker 2:
2:27
Right and in your experience, you encountered another health care professional who heard about this big result that came out, this clinical study, the results of this study, and they felt that that was just maybe a group of docs that had an opinion about it. But indeed there might be a little bit of a misunderstanding as to exactly what clinical research results are.
Speaker 3:
2:45
Yeah, yeah, thanks for bringing that up. I had an interesting interaction at the gym, as a matter of fact, and I overheard some people talking about ozempic and there was a retired dentist there it was part of the discussion talking with some other people who were wondering if they should use ozempic. And yeah, I usually keep my mouth shut, but it got to a point where I had to say something and the doctor would say oh ozempic, you don't need ozempic, Just do a diet and exercise. If you, in my opinion, if you just work hard to diet and exercise, you don't need any drugs. That's what he said and I had a chime in at that point. And certainly I'm a huge advocate of diet and exercise. But the opinion that diet and exercise supplants any medicine, I think, is a little bit of extreme.
Speaker 3:
3:32
And when we started talking about the ozempic results that you just alluded to, kevin, he kind of poo pooed them and I just reminded him that this is a clinical trial. This is the results of a game. We put out, a study that looked at people taking ozempic versus the exact same people who were taking a placebo. So everything else was the same except whether or not you were taking ozempic and the people taking ozempic not only lost weight, but they had fewer heart attacks and strokes. So that's just the results of a game, and you may not favor ozempic or drugs, or you may favor diet and exercise, but at the end of the day, tens of thousands of people who are in this study showed that this particular product reduced heart attacks and strokes and led to weight loss.
Speaker 2:
4:13
Yeah, and that's the key takeaway. Right, there's clinical research that, of course, our listeners can participate right here in St Augustine. Results in facts, right, results in data that is fairly concrete. It's not just someone's opinion.
Speaker 3:
4:28
Exactly exactly. It's again. It's just playing out the game. We have a hypothesis, we test the hypothesis and then the results come out, and then we explain the results to the public.
Speaker 2:
4:39
Yeah, and you could participate in this, obviously, benefit from some amazing healthcare, be on the leading edge of medicine all that, all those benefits and even get paid a little bit for participating. And you can do that right here in St John's County, on core. Of course has offices near Flagler Hospital in St Augustine. You can learn more by calling 904-7 301-66904-730-0166. Dr Michael Korn, any closing thoughts before we let you go?
Speaker 3:
5:08
No, just again. In another session we can talk about why sometimes people hear conflicting clinical trial results. So maybe that'll be a tease for next week. But, the fact is is that, when the results come out, it is the answer to the question, and you may not want to believe it, but you should.
Speaker 2:
5:30
Yeah, absolutely. And speaking of clinical research and the results and the data that comes from, and a really good website that Dr Michael Korn is very involved with, check this one out medevidencecom. That's medevidencecom. We're going to hear a discussion of some facts, right, dr Korn? You bet, you bet Kevin. Thank you, dr, thanks for joining us and we'll talk with you next week.
Speaker 1:
5:51
Oh, it's a pleasure. Thanks for joining the MedEvidence podcast. To learn more, head over to medevidencecom or subscribe to our podcast on your favorite podcast platform.
